Patents Expiring in December 2044
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | 11,878,022 | ⤷ Start Trial | Y | TREATMENT OF EDEMA IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | |||
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | 11,878,022 | ⤷ Start Trial | Y | TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | |||
| Amivas | ARTESUNATE | artesunate | POWDER;INTRAVENOUS | 213036-001 | May 26, 2020 | RX | Yes | Yes | 12,390,442 | ⤷ Start Trial | A METHOD OF TREATING MALARIA USING MICRONIZED POWDER OF CRYSTALLINE ARTESUNATE PREPARED BY STERILIZING AND FILLING THE POWDER INTO A CONTAINER AT A RELATIVE HUMIDITY OF 30 TO 40%, MIXING THE POWDER WITH A BUFFER AND ADMINISTERING THE COMPOSITION | ||||
| Amivas | ARTESUNATE | artesunate | POWDER;INTRAVENOUS | 213036-001 | May 26, 2020 | RX | Yes | Yes | 12,121,506 | ⤷ Start Trial | Y | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
